Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor κB activation and C-reactive protein expression in human carotid artery plaques

Stroke

Volumn 36, Issue 1, 2005, Pages 14-20

  Sattler, Katherine J E ^a   Woodrum, Julie E ^a   Galili, Offer ^a   Olson, Monica ^a   Samee, Saquib ^a   Meyer, Fredric B ^a   Zhu, Xiang Yang ^a   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

Aspirin; Atherosclerosis; Carotid endarterectomy; Growth factors; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CD40 LIGAND; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; WESTERN BLOTTING;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; C-REACTIVE PROTEIN; CAROTID STENOSIS; CD40 LIGAND; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; MALE; NF-KAPPA B;

EID: 11144236265     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000150643.08420.78     Document Type: Article

References (51)

1. Plutzky J. Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol. 2001;88:10K-15K.
2. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol. 2003;91:3A-6A.
3. de Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol. 2000;20:e83-e88.
4. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmid C, Bauerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715-1722.
5. Wilson SH, Best PJ, Edwards WD, Holmes DR Jr, Carlson PJ, Celermajer DS, Lerman A. Nuclear factor-κB immunoreactivity is present in human coronary plaque and enhanced in patients with unstable angina pectoris. Atherosclerosis. 2002;160:147-153.
6. Ritchie M. Nuclear factor-κB is selectively and markedly activated in humans with unstable angina pectoris. Circulation. 1998;98:1707-1713.
7. Touyz RM, Berry C. Recent advances in angiotensin II signaling. Braz J Med Biol Res. 2002;35:1001-1015.
8. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep. 2003;5: 73-79.
9. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Overexpressed nuclear factor-κB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPb and signal transducer and activator of transcription-3. Immunology. 2003;108:539-547.
10. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation. 2003;107:1783-1790.
11. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Circulation. 2003;107:398-404.
12. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res. 2003;58:186-195.
13. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy. C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-919.
14. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102: 2165-2168.
15. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schoenbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor κB, and Egr-1. J Biol Chem. 2002;277:25032-25039.
16. Mach F, Schoenbeck U, Sukhova G, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A. 1997;94:1931-1936.
17. Hosono M, de Boer OJ, van der Wal AC, van der Loos CM, Teeling P, Piek JJ, Ueda M, Becker AE. Increased expression of T cell activation markers (CD25, CD26, CD40L and CD69) in atherectomy specimens of patients with unstable angina and acute myocardial infarction. Atherosclerosis. 2003;168:73-80.
18. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M. Canonical pathway of nuclear factor κB activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci U S A. 2004:101:5634-5639.
19. 2 in human endothelial cells by engagement of CD40. Atherosclerosis. 2002; 163:9-16.
20. Schrier DJ, Ripani LM, Katzenstein AL, Moore VL. Role of angiotensin-converting enzyme in Bacille Calmette-Guerin-induced granulomatous inflammation. Increased angiotensin-converting enzyme levels in lung lavage and suppression of inflammation with captopril. J Clin Invest. 1982;69:651-657.
21. Ruiz-Ortega M, Gonzalez S, Seron D, Condom E, Bustos C, Largo R, Gonzalez E, Ortiz A, Egido J. ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int. 1995;48:1778-1791.
22. Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL, Taylor JM, Wolfe LF, Brizio-Molteni L, Veno P. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol. 2000;76: 523-532.
23. Kuno A, Yamada T, Masuda K, Ogawa K, Sogawa M, Nakamura S, Nakazawa T, Ohara H, Nomura T, Joh T, Shirai T, Itoh M. Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology. 2003;124: 1010-1019.
24. Yamamoto K, Shioi T, Uchiyama K, Miyamoto T, Sasayama S, Matsumori A. Attenuation of virus-induced myocardial injury by inhibition of the angiotensin II type 1 receptor signal and decreased nuclear factor-kappa B activation in knockout mice. J Am Coll Cardiol. 2003; 42:2000-2006.
25. Vane JR. Back to an aspirin a day? Science. 2002;296:474-475.
26. Coletta AP, Cleland JGF, Freemantle N, Loh H, Memon A, Clark AL. Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA, and ESTEEM. Eur J Heart Fail. 2003;5:697-704.
27. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324:1-5.
28. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163:2006-2010.
29. Rodriguez-Porcel M, Lerman LO, Holmes DR Jr. Richardson D, Napoli C, Lerman A. Chronic antioxidant supplementation attenuates nuclear factor-kappa B activation and preserves endothelial function in hypercholesterolemic pigs. Cardiovasc Res. 2002;53:1010-1018.
30. Zhu X-Y, Rodriguez-Porcel M, Bentley MD, Chade AR, Sica V, Napoli C, Caplice N, Ritman EL, Lerman A, Lerman LO. Antioxidant intervention attenuates myocardial neovascularization in hypercholesterolemia. Circulation. 2004;109:2109-2115.
31. Gould JM, Weiser JN. Expression of C-reactive protein in the human respiratory tract. Infect Immun. 2001;69:1747-1754.
32. Jabs WJ, Logering BA, Gerke P, Kreft B, Wolber EM, Klinger MH, Fricke L, Steinhoff J. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol. 2003;33:152-161.
33. Jabs WJ, Theissing E, Nitschke M, Bechtel JFM, Duchrow M, Mohamed S, Jahrbeck B, Sievers HH, Steinhoff J, Bartels C. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation. 2003;108:1428-1431.
34. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages. Implications for atherosclerosis. Circulation. 2001;103:1194-1197.
35. Ishikawa T, Hatakeyama K, Imamura T, Date H, Shibata Y, Hikichi Y, Asada Y, Eto T. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol. 2003;91:287-292.
36. Andrie R, Maylahn M, Braun P, Luederitz B, Bauriedel G. C-reactive protein in coronary plaques: prevalence with acute coronary syndrome. Z Kardiol. 2002;91:913-920. German
37. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105:1890-1896.
38. Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, Li RK, Mickle DA. C-reactive protein activates the nuclear factor-κB signal transduction pathway in saphenous vein endothelial cells: Implications for atherosclerosis and restenosis. The J Thorac Cardiovasc Surg. 2003; 126:1886-1891.
39. Williams TN, Zhang CX, Game BA, He L, Huang Y. C-reactive protein stimulates MMP-1 expression in U937 histiocytes through FcγRII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization. Arterioscler Thromb Vasc Biol. 2004;24:61-66.
40. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol. 2001;38:189-197.
41. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factor. Circ Res. 1999;84: 695-703.
42. Dzau VJ, Bernstein K, Celermaier D, Cohen J, Dahloef B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, Hansson L, Hornig B, Husain A, Johnston C, Lazar H, Lonn E, Luescher T, Mancini J, Mimran A, Pepine C, Rabelink T, Remme W, Ruilope L, Ruzicka M, Schunkert H, Swedberg K, Unger T, Vaughan D, Weber M. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol. 2001;88:1L-20L.
43. Hu ZW, Kerb R, Shi XY, Wei-Lavery T, Huffman BB. Angiotensin II increases expression of cyclooxigenase-2: implications for the function of vascular smooth muscle cells. J Pharmacol Exp Ther. 2002;303:563-573.
44. Zahradka P, Werner JP, Buhay S, Litchie B, Helwer G, Thomas S. NF-κB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol. 2002;34: 1609-1621.
45. Hernandez-Presa MA, Bustos C, Ortega M, Tunon J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-κB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol. 1998;153:1825-1837.
46. Chen H, Li D, Mehta JL. Modulation of matrix metalloproteinase-1, its tissue inhibitor and nuclear factor-κB by losartan in hypercholesterolemic rabbits. J Cardiovasc Pharmacol. 2002;39:332-339.
47. Weber C, Erl W, Pietsch A, Weber PC. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation. 1995;91:1914-1917.
48. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I kappa B kinase-beta. Nature. 1998;396:77-80.
49. Muller DN, Heissmeyer V, Dechend R, Hampich F, Park JK, Fiebeler A, Shagdasuren E, Theuer J, Elger M, Pilz B, Breu V, Schroer K, Ganten D, Dietz R, Haller H, Scheidereit C, Luft FC. Aspirin inhibits NF-κB and protects from angiotensin II-induced organ damage. FASEB J. 2001;15: 1822-1824.
50. Costanzo A, Moretti F, Burgio VL, Bravi C, Guido F, Levrero M, Puri PL. Endothelial activation by angiotensin II through NFκB and p38 pathways: involvement of NFκB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol. 2003;195: 402-410.
51. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant. Eur Heart J. 2003;24:225-248.